These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 122683

  • 1. Penicillamine therapy in systemic sclerosis.
    Jayson MI, Lovell C, Black CM, Wilson RS.
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):82-8. PubMed ID: 122683
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Progressive systemic sclerosis and penicillamine.
    Rodnan GP.
    J Rheumatol Suppl; 1981; 7():116-20. PubMed ID: 6939873
    [Abstract] [Full Text] [Related]

  • 4. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine [see comment].
    Jimenez SA, Sigal SH.
    J Rheumatol; 1991 Oct; 18(10):1496-503. PubMed ID: 1765974
    [Abstract] [Full Text] [Related]

  • 5. D-penicillamine treatment of progressive systemic sclerosis (scleroderma): a comparison of clinical and in vitro effects.
    Shapiro LS, Prince RK, Buckingham RB, Rodnan GP.
    J Rheumatol; 1983 Apr; 10(2):316-8. PubMed ID: 6864687
    [Abstract] [Full Text] [Related]

  • 6. [Systemic sclerosis].
    Gustafsson R.
    Nord Med; 1994 Apr; 109(8-9):236-7. PubMed ID: 7937033
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of systemic scleroderma with D-penicillamine. Results in 14 patients treated for more than a year].
    Kahn MF, Bourgeois P, Brion N, Elleuch M.
    Rev Rhum Mal Osteoartic; 1986 Jan; 53(1):35-8. PubMed ID: 3704510
    [Abstract] [Full Text] [Related]

  • 8. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
    Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR.
    Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
    [Abstract] [Full Text] [Related]

  • 9. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ.
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of generalized scleroderma with inhibitors of connective tissue formation.
    Asboe-Hansen G.
    Acta Derm Venereol; 1975 Nov; 55(6):461-5. PubMed ID: 55038
    [Abstract] [Full Text] [Related]

  • 12. [D-penicillamine in the treatment of progressive systemic sclerosis].
    Marques Neto JF, Manzato LC, Samara AM.
    AMB Rev Assoc Med Bras; 1980 Jun; 26(6):191-3. PubMed ID: 6970374
    [No Abstract] [Full Text] [Related]

  • 13. [Treatment of interstitial pulmonary fibrosis with D-penicillamine in progressive scleroderma: a long-term study (author's transl)].
    Bröll H, Tausch G, Eberl R.
    Wien Klin Wochenschr; 1976 Apr 30; 88(9):292-5. PubMed ID: 973388
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Renal scleroderma crisis. Role of scleroderma vasculopathy in the induction of cutaneous and visceral fibrosis in 2 cases].
    Cuchacovich M, Holuigue G, Gatica H, Alvo M, Murray G.
    Rev Med Chil; 2000 Jan 30; 128(1):86-92. PubMed ID: 10883527
    [Abstract] [Full Text] [Related]

  • 16. D-penicillamine induced crescentic glomerulonephritis: report and review of the literature.
    Devogelaer JP, Pirson Y, Vandenbroucke JM, Cosyns JP, Brichard S, Nagant de Deuxchaisnes C.
    J Rheumatol; 1987 Oct 30; 14(5):1036-41. PubMed ID: 3430507
    [Abstract] [Full Text] [Related]

  • 17. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
    Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J.
    Arthritis Rheum; 1999 Nov 30; 42(11):2372-80. PubMed ID: 10555033
    [Abstract] [Full Text] [Related]

  • 18. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
    Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Furst DE.
    Arthritis Rheum; 2000 Nov 30; 43(11):2445-54. PubMed ID: 11083267
    [Abstract] [Full Text] [Related]

  • 19. Does long-term treatment with D-penicillamine alter calcium and phosphorus metabolism in patients with systemic sclerosis?
    Hagdrup H, Serup J, Tvedegaard E.
    Acta Derm Venereol; 1983 Nov 30; 63(5):447-9. PubMed ID: 6197850
    [Abstract] [Full Text] [Related]

  • 20. Treatment of systemic sclerosis.
    Wigley FM.
    Curr Opin Rheumatol; 1992 Dec 30; 4(6):878-86. PubMed ID: 1457284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.